Peptide Free Base, Salt Form, Counterions, and Labeled Mass

“Peptide acetate” and “peptide free base” may refer to a related active moiety, but they do not describe the same bulk composition or automatically use the same mass basis. Counterions contribute to the chemical form and measured mass. Water, solvent, or variable counterion occupancy may also matter. A responsible record therefore separates the peptide moiety, the salt or other associated form, the amount basis, and the evidence for the actual lot.

FDA’s salt-naming guidance has a specific regulatory scope: it explains how CDER applies the USP Salt Policy to names and strengths of prescription drug products containing salt drug substances under the Federal Food, Drug, and Cosmetic Act. It does not address nonprescription products or biological products licensed under the Public Health Service Act.[1] It is not a general authorization to relabel research materials, and its active-moiety convention does not make bulk salt and neutral forms interchangeable.

Four layers should not be collapsed

These layers affect record interpretation.

Active moiety is a regulatory concept, not a bulk-form synonym

FDA’s current Orange Book preface cites the regulatory definition of active moiety as the molecule or ion responsible for action, excluding appended portions that make it a salt or certain other noncovalent derivatives.[2] That definition serves regulatory purposes. It does not say that the active moiety and every one of its salt forms have identical formulas, masses, physical properties, specifications, or analytical behavior.

FDA’s guidance describes active-moiety-based naming and strength for affected new prescription drug products and recommends accompanying equivalency statements. It leaves existing statutory and regulatory active-ingredient labeling requirements intact and recognizes defined exceptions.[1] The key reading lesson is to locate both statements. The front-facing strength may be active-moiety based even though the material used to formulate the product is a salt.

Counterions are part of the stated material form

Charged peptide groups can be associated with oppositely charged ions. A salt description should identify the relevant counterion and, when applicable, its stoichiometry or justified range. FDA’s ICH Q6A guidance says that identification testing for a salt should be specific for the individual ions or for the salt itself within its chemical-drug scope.[3] It also treats hydration state and stereochemical identity as potentially distinct specification questions.

“Acetate” conveys more than a casual synonym. “TFA” commonly abbreviates trifluoroacetic acid; “TFA salt” often denotes a trifluoroacetate-associated form. PubChem identifies trifluoroacetate as an anion with formula C2F3O2− and its own CID.[6] The shorthand does not state its amount or stoichiometry, other ions, or the labeled mass basis. PubChem is a chemical database, not sample verification.

Why the labeled number can use a different basis

Mass is meaningful only when the measured entity is defined. “Milligrams of peptide” could mean:

• mass of the active moiety;
• mass of a named salt;
• mass corrected for water, solvent, or counterion;
• total dry-material mass; or
• a value derived from an assay against a reference.

Those values need not be numerically equal. Adding counterion or bound solvent changes the mass of the complete material without adding the same mass of peptide moiety. Variable stoichiometry can make a single theoretical salt formula inappropriate unless the controlling record defines a range.

A molecular-weight entry also needs a stated entity. A value labeled “free base” should not be silently used as the formula mass of a salt. Conversely, a salt mass should not be reported as active-moiety mass without the governing equivalency and analytical basis.

Worked label example: bremelanotide acetate

The current DailyMed label for the named finished product Vyleesi identifies bremelanotide acetate with a formula written as the peptide plus xCH3COOH, where 1 ≤ x ≤ 2. It separately reports a molecular-weight value as the free-base basis. The same description states that a prefilled presentation contains 1.75 mg bremelanotide, equivalent to 1.89 mg bremelanotide acetate.[4]

This one label demonstrates three distinctions:

1. the active-moiety name is bremelanotide;
2. the active ingredient is represented as an acetate form with variable stated association; and
3. the labeled active-moiety amount and salt-equivalent amount are different numbers.

The relationship is specific to that label and entity. It is not a general acetate conversion, and it cannot be applied to another peptide, another stoichiometry, or an unidentified catalog material.

Worked label example: tesamorelin acetate

The current Egrifta WR DailyMed label describes tesamorelin as an acetate salt and writes its formula with approximately seven acetate equivalents. It reports a molecular weight on a free-base-equivalent basis. The label also distinguishes 11.6 mg tesamorelin from approximately 11.9 mg tesamorelin acetate in the named vial.[5]

These are separately printed label statements, not a validated conversion equation. This guide preserves their stated approximation without deriving or reconciling a salt-mass conversion from them. No percentage adjustment should be transferred to another material.[5]

Free base, free acid, and neutral form need precise wording

“Free base” is often used for a basic active moiety without its salt-forming counterion. For an acidic molecule, “free acid” may be the corresponding phrase. Peptides can contain several ionizable groups, so their charge depends on conditions; casual acid–base wording may oversimplify a multi-site molecule.

The safest record states the exact defined entity and repeats the source’s mass convention. Do not infer a neutral isolated species merely because a label uses active-moiety strength. Regulatory strength expression and the physical form of the ingredient answer different questions.[1][2]

Read identifiers at the same level as the substance

FDA’s GSRS creates UNIIs from standardized substance definitions for regulatory data exchange.[7] Chemically related forms can have distinct records or relationships. When reviewing a label or certificate, check whether its UNII, formula, and name refer to the active moiety, salt, counterion, or finished product ingredient.

An identifier match is not lot authentication. FDA says UNIIs can be generated throughout the regulatory lifecycle; therefore, their availability alone is not approval evidence.[7] A CAS number or PubChem CID likewise identifies a database concept, not a particular container’s contents, purity, sterility, or composition.

Counterion content requires a suitable measurement

A peptide peak-area percentage does not, by itself, provide a quantitative counterion result. The record should identify which ion was measured and the procedure used. In a 2004 analytical study, Kaiser and Rohrer separated trifluoroacetate by anion-exchange chromatography and detected it by suppressed conductivity in buffers and a commercial peptide preparation. That demonstrates one measurement approach; its performance in those samples does not establish suitability for every peptide matrix.

Likewise, a stated exchange process is not a measured residual result. Roux and colleagues compared counterion-exchange approaches in lanreotide and assessed their outcomes with NMR and infrared methods. The findings were method- and material-specific. For a lot report, request the ion identity, numerical result, units, reporting limit, moisture basis and evidence that the method is selective for the sample. An acetate label alone cannot establish that residual trifluoroacetate is below a particular threshold.

What a useful analytical record should say

For a peptide supplied as a salt or counterion-associated material, the evidence package should identify:

1. the complete peptide structure, including termini and modifications;
2. the named counterion or associated component;
3. stated or measured stoichiometry, including any allowed range;
4. water and solvent basis where material to the result;
5. the denominator used for assay or content reporting;
6. the reference material and calculation convention;
7. the lot tested and the result date; and
8. method limitations and acceptance criteria.

No one field proves the rest. For example, a counterion test does not establish peptide sequence, while a peptide mass result may not quantify counterion content.

Study-to-catalog and lot boundary

A paper may report a peptide by active-moiety name and omit salt detail. A regulatory label may fully specify a named finished product. A research-material listing may list an acetate form or use “TFA salt” wording without stoichiometry or amount basis. The approved-drug versus research-material guide explains why those records cannot be merged by assumption.

Before claiming that a study material matches a catalog material, the sequence, termini, modifications, associated form, amount basis, formulation, and relevant lot evidence must align. Even then, identity evidence is separate from purity, sterility, potency, stability, and regulatory status.

Common record-reading errors

• Treating “as acetate” and “free base” as interchangeable mass descriptions.
• Applying one product’s equivalency ratio to another peptide.
• Ignoring a variable x in a formula.
• Assuming “TFA” states a measured amount or fixed stoichiometry.
• Using an active-moiety strength as proof of the bulk ingredient’s physical form.
• Treating a UNII, CAS number, or formula as a lot certificate.
• Inferring approval or finished-product equivalence from a shared active-moiety name.

Important limitations

• A shared active moiety does not make salt forms, counterions, hydrates, or mass bases interchangeable.
• Counterion identity does not establish counterion amount, peptide content, or lot purity.
• Formula and molecular-mass values are meaningful only for the defined entity and convention.
• A label equivalency applies to the named finished product record, not all materials with a similar name.
• Identifier records do not prove identity, purity, sterility, potency, approval, or chain of custody for a lot.
• Study reports often omit material-form details needed for catalog matching.
• This page provides no preparation, conversion, administration, or use instruction.

Frequently asked questions

Is peptide acetate the same as peptide free base?

They can share an active moiety, but the complete material forms and masses differ. Equivalence must be stated for the specific entity and basis; it cannot be assumed from the name.

Why can a label show two milligram numbers for one ingredient?

One number may express active-moiety mass and another the corresponding salt mass. The Vyleesi and Egrifta WR labels provide product-specific examples.[4][5]

Does “acetate” tell me the exact acetate content?

Not always. The controlling source may give a fixed coefficient, an approximate value, a range, or no stoichiometry. Preserve that level of certainty.

Does “TFA salt” establish how much trifluoroacetate is present?

No. It names an associated form but does not by itself state quantity, stoichiometry, hydration, residual content, or the basis of a labeled mass.[3][6]

Can I calculate salt mass from a free-base molecular weight alone?

Not reliably without a defined formula, counterion stoichiometry, hydration or solvation state, and amount basis. This guide intentionally does not provide a universal conversion.

Does a UNII prove the material is approved or that a lot matches it?

No. FDA says UNIIs can be generated throughout the regulatory lifecycle. Identifier availability alone is therefore not approval or lot evidence.[7]

Can study findings transfer across free-base and salt-form records?

Not by name alone. The study material and comparison material must be reconciled across structure, form, amount basis, formulation, and lot-specific evidence.

Primary and official sources

1. FDA: Naming of Drug Products Containing Salt Drug Substances
2. FDA: Orange Book Preface and Active-Moiety Definition
3. FDA: ICH Q6A Specifications for Chemical Drug Substances and Products
4. DailyMed: Vyleesi (Bremelanotide) Current Label
5. DailyMed: Egrifta WR (Tesamorelin) Current Label
6. NLM PubChem: Trifluoroacetate, CID 84468
7. FDA: Global Substance Registration System and UNIIs

Review and corrections

Sources checked: September 2, 2026. Questions or corrections can be sent through the Serum Research contact page.

Editorial responsibility: Serum Research prepared and maintains this educational page. No independent scientific, analytical, regulatory, or clinical review is claimed. This evidence-reading guide does not provide medical advice or establish the identity, quality, safety, effectiveness, or equivalence of any catalog material or lot. See how Serum Research reviews evidence or return to the Research Peptide and Compound Library.